APA (7th ed.) Citation

S, P., S, W., AM, B., J, O., LS, S., E, B., . . . L, V. (2016). Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: Results from a Phase II, single-arm, multicenter study. Dove Medical Press.

Chicago Style (17th ed.) Citation

S, Puhalla, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, and Vahdat L. Clinical Effects of Prior Trastuzumab on Combination Eribulin Mesylate Plus Trastuzumab as First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results from a Phase II, Single-arm, Multicenter Study. Dove Medical Press, 2016.

MLA (8th ed.) Citation

S, Puhalla, et al. Clinical Effects of Prior Trastuzumab on Combination Eribulin Mesylate Plus Trastuzumab as First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results from a Phase II, Single-arm, Multicenter Study. Dove Medical Press, 2016.